Total Payments
$214,835
2024 Payments
$1,687
Companies
13
Transactions
230
Medicare Patients
687
Medicare Billing
$65,902
Payment Breakdown by Category
Other$167,275 (77.9%)
Consulting$29,311 (13.6%)
Travel$11,854 (5.5%)
Food & Beverage$5,907 (2.7%)
Research$461.85 (0.2%)
Education$26.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $167,275 | 78 | 77.9% |
| Consulting Fee | $29,311 | 13 | 13.6% |
| Travel and Lodging | $11,854 | 52 | 5.5% |
| Food and Beverage | $5,907 | 83 | 2.7% |
| Unspecified | $461.85 | 1 | 0.2% |
| Education | $26.68 | 3 | 0.0% |
Payments by Type
General
$214,373
229 transactions
Research
$461.85
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $116,475 | 124 | $0 (2022) |
| Seagen Inc. | $32,868 | 29 | $0 (2023) |
| Daiichi Sankyo Inc. | $27,404 | 26 | $0 (2023) |
| EISAI INC. | $24,835 | 17 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $6,645 | 9 | $0 (2023) |
| Gilead Sciences, Inc. | $3,218 | 3 | $0 (2024) |
| AstraZeneca UK Limited | $1,611 | 10 | $0 (2024) |
| Genentech, Inc. | $563.00 | 3 | $0 (2022) |
| Eli Lilly and Company | $559.51 | 2 | $0 (2021) |
| Genentech USA, Inc. | $358.83 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,687 | 12 | AstraZeneca UK Limited ($1,611) |
| 2023 | $21,993 | 23 | Seagen Inc. ($9,416) |
| 2022 | $50,668 | 44 | Lilly USA, LLC ($21,097) |
| 2021 | $18,073 | 18 | Seagen Inc. ($8,230) |
| 2020 | $18,586 | 38 | Lilly USA, LLC ($12,199) |
| 2019 | $45,361 | 39 | Lilly USA, LLC ($35,677) |
| 2018 | $46,538 | 43 | Lilly USA, LLC ($40,852) |
| 2017 | $11,929 | 13 | Eisai Inc. ($9,673) |
All Payment Transactions
230 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/30/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $45.75 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $584.68 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $407.39 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $59.00 | General |
| 01/30/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $781.75 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $144.75 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $115.50 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.50 | General |
| 12/03/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $368.27 | General |
| 07/07/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,160.00 | General |
| Category: ONC | ||||||
| 06/22/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 06/22/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $122.88 | General |
| Category: Oncology | ||||||
| 05/23/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $66.81 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $30.49 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $461.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 125 | 203 | $51,185 | $12,029 |
| 2022 | 3 | 147 | 251 | $66,218 | $16,404 |
| 2021 | 5 | 193 | 305 | $68,049 | $20,823 |
| 2020 | 6 | 222 | 317 | $63,931 | $16,646 |
Total Patients
687
Total Services
1,076
Medicare Billing
$65,902
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 89 | $26,789 | $6,658 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 94 | 114 | $24,396 | $5,371 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 119 | $35,379 | $9,110 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 117 | $24,544 | $5,509 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 15 | $6,295 | $1,784 | 28.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 139 | $35,723 | $10,836 | 30.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 83 | 95 | $16,720 | $4,679 | 28.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 34 | 38 | $7,549 | $2,846 | 37.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $5,835 | $1,693 | 29.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 18 | 18 | $2,222 | $769.35 | 34.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 129 | $33,153 | $7,573 | 22.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 77 | 83 | $14,608 | $2,878 | 19.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 47 | 53 | $3,498 | $2,089 | 59.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $5,835 | $1,624 | 27.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 22 | 24 | $2,352 | $1,414 | 60.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 12 | 13 | $4,485 | $1,068 | 23.8% |
About Dr. William Sikov, MD
Dr. William Sikov, MD is a Hematology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811916661.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Sikov, MD has received a total of $214,835 in payments from pharmaceutical and medical device companies, with $1,687 received in 2024. These payments were reported across 230 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($167,275).
As a Medicare-enrolled provider, Sikov has provided services to 687 Medicare beneficiaries, totaling 1,076 services with total Medicare billing of $65,902. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Providence, RI
- Active Since 07/19/2006
- Last Updated 06/16/2021
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1811916661
Products in Payments
- VERZENIO (Drug) $108,444
- TUKYSA (Drug) $32,837
- Halaven (Drug) $24,835
- Enhertu (Drug) $15,911
- ENHERTU (Drug) $11,493
- ENHERTU (Biological) $3,425
- Trodelvy (Drug) $3,160
- LYNPARZA (Drug) $1,611
- Herceptin (Biological) $358.83
- FOUNDATIONONE (Device) $200.25
- FASLODEX (Drug) $96.32
- FOUNDATIONACT (Device) $65.91
- Orserdu (Drug) $29.74
- ELIQUIS (Drug) $3.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Providence
Kimberly Perez
Hematology — Payments: $146,048
Hematology $146,048
Wafik El Deiry, Md, MD
Hematology — Payments: $3,821
Hematology $3,821
Dr. Jeremy Warner, Md, MD
Hematology — Payments: $2,900
Hematology $2,900
Angela Taber, Md, MD
Hematology — Payments: $1,379
Hematology $1,379
Sherise Rogers, M.d, M.D
Hematology — Payments: $375.85
Hematology $375.85
Mirela Stancu, M.d, M.D
Hematology — Payments: $226.97
Hematology $226.97